Thema: US92686J1060
VKTX, US92686J1060
covid-19-4987726_1280.jpg - Foto: THN
Viking Therapeutics stock: VK2735 programs advance after Q3 update
Viking Therapeutics outlined progress in its obesity pipeline after its third-quarter update. Oral and injectable VK2735 programs remain central to its next clinical steps.
ad-hoc-news.de, heute 13:26 Uhr
VKTX, US92686J1060
Viking Therapeutics reports wider loss: what it means for ...
Third-quarter loss reached USD 183.2 million on September 30, 2026. Viking Therapeutics stock stood at EUR 22.13 on October 29, 2026.
ad-hoc-news.de, 29.10.26 14:10 Uhr
VKTX, US92686J1060
Canaccord trims target for Viking Therapeutics stock
Viking starts two oral Phase 3 studies on October 14, 2026 with 560 adults each. Canaccord cut its target to USD 106 for Viking Therapeutics stock.
ad-hoc-news.de, 27.10.26 14:40 Uhr
VKTX, US92686J1060
Viking Therapeutics sets October 28 results date for Viking ...
Viking will report third-quarter results on October 28 after the close. A 4:30 p.m. ET call gives Viking Therapeutics stock its next test.
ad-hoc-news.de, 25.10.26 13:47 Uhr
VKTX, US92686J1060
UBS sets USD 94 target for Viking Therapeutics stock
Viking starts two oral SUNRISE studies of 560 adults over 68 weeks. Viking Therapeutics stock costs EUR 22.38 on October 20, 2026 before October 28 results.
ad-hoc-news.de, 20.10.26 13:29 Uhr
VKTX, US92686J1060
H.C. Wainwright targets Viking Therapeutics stock at USD ...
Viking starts oral VK2735 Phase 3 studies with 560 adults each. Viking Therapeutics stock faces 68-week trials after H.C. Wainwright set a USD 102.00 target.
ad-hoc-news.de, 18.10.26 13:47 Uhr
VKTX, US92686J1060
Viking starts oral Phase 3 program for Viking Therapeutics ...
SUNRISE-1 and SUNRISE-2 will each enroll 560 adults in the oral VK2735 trials. Viking Therapeutics stock has a USD 102.00 target.
ad-hoc-news.de, 15.10.26 12:34 Uhr
VKTX, US92686J1060
Viking Therapeutics stock fell 3.07 percent as oral trial ...
Viking Therapeutics stock began oral VK2735 maintenance testing on October 6, 2026. Q2 loss reached USD 1.10 per share against a USD 1.21 consensus loss.
ad-hoc-news.de, 07.10.26 05:11 Uhr
VKTX, US92686J1060
Viking Therapeutics starts oral trial as Truist targets ...
Viking starts an oral obesity trial on October 6, 2026. Viking Therapeutics stock spans USD 25.77 to USD 43.15 at USD 3.3 billion on October 6, 2026.
ad-hoc-news.de, 07.10.26 01:49 Uhr
